About Event
What Can You Expect at the GPCRs-Targeted Drug Development Summit?
With increasing interest in Class B GPCRs, such as the GLP-1 receptor, and massive technological advances in screening and drug design, GPCR drug discovery is constantly evolving.
This meeting will allow you to stay at the fore-front of drug discovery and keep your finger on the pulse of all things GPCR. Uniting the sharpest minds in the European GPCR community, this forum will pioneer the next wave of GPCR therapeutic potential.
With 3-days of technically driven content, this Meeting will focus on revolutionary approaches to drug design, breakthroughs in structural biology, the latest computational tools and novel therapeutic targets, enabling you to progress your small molecules and biologics into clinically relevant GPCR drugs.
Join Your GPCR Peers to:
Leverage the power of human genetics by linking the molecular, cellular, and clinical consequences of rare GPCR missense variations to accelerate the discovery of disease relevant pathways, with insights from ThirtyFiveBio & Domain Therapeutics
Uncover novel mechanisms by expanding your screening, computational and assay toolbox to identify a comprehensive workflow to accelerate your discovery pipelines into promising pre-clinical candidates, with insights from Roche & Eli Lilly
Enhance the pharmacology of your small molecules and biologics to reach previously undruggable GPCR targets to address diseases with unmet patient needs, with insights from Orion Biotechnology & Starget Pharma
Employ structural predictions and molecular dynamics to better confer the cooperativity of receptors and candidates towards effective GPCR-targeting therapies, with insights from AstraZeneca & Confo Therapeutics
Improve the probability of your clinical success by identifying and validating disease-relevant biomarkers with high-translational value to bring safe and effective GPCRs drugs to patients faster, with insights from OMass Therapeutics & Pathios Therapeutics